US and MCUG for all children aged <2 years. 99m Tc–DMSA scan in high-grade reflux [3] Urinary tract infection (UTI) is the most common serious bacterial infection in childhood, and its ...

The Food and Drug Administration (FDA) has approved a new drug for treating urinary tract infections (UTIs), the first such drug approved in decades and the first in a new class of medications.

The U.S. Food and Drug Administration (FDA) has approved Blujepa (gepotidacin), a novel oral antibiotic, for the treatment of uncomplicated urinary tract infections (uUTIs) in adult women and children ...

The approval of the new drug is based on positive results from the Phase III EAGLE-2 and EAGLE-3 trials.

Gepotidacin is an oral, first-in-class triazaacenaphthylene antibiotic that inhibits bacterial DNA replication by blocking 2 different type II topoisomerase enzymes. Study participants were ...

The US Food and Drug Administration has approved a new type of antibiotic to treat urinary tract infections. The pill, gepotidacin, will be sold under the brand name Blujepa and is expected to be ...

Gepotidacin is a first-in-class triazaacenaphthylene antibiotic with a novel mechanism, inhibiting bacterial DNA replication at a distinct binding site. Phase 3 trials EAGLE-2 and EAGLE-3 showed ...

A GSK pill that offers a lower potential for drug resistance is now FDA approved as a new treatment for a common type of urinary tract infection, the first new oral antibiotic for this indication ...

A new antibiotic has been approved to treat urinary tract infections by the Food and Drug Administration for the first time in decades. It’s an oral pill called Blujepa from the London-based biopharma ...